Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
AerCap is using tight aircraft supply to produce record earnings, asset-sale gains and buybacks. The upside is real, but the model still runs on leverage, airline customer health and aircraft residual values.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Rocket Lab reported FY2025 revenue of $601.8 million, Q1 2026 revenue of $200.3 million, a FY2025 net loss of $198.2 million and $1.2 billion of cash. The thesis depends on launch cadence, space systems demand, Neutron investment, operating leverage, cash burn
OpenBoeing is a globally strategic aerospace franchise with FY2025 revenue of $89.5 billion and Q1 2026 revenue of $22.2 billion, but the investment case still turns on production discipline, safety oversight, defense charges and recurring cash generation.
OpenAgios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
OpenAeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, s
OpenArcher has enough liquidity to make the eVTOL race worth watching, but the filings still show a pre-revenue aircraft company burning cash while certification, manufacturing, launch operations, conditional orders, and IP fights decide whether Midnight becomes a
OpenTag facets appear after tag usage counts are rebuilt.